Targets › COL3A1
3 programs from 3 companies in 8 trials: 5 Phase 4, 1 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Genitourinary, Other; next expected readout Dec 2027.
Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. (UniProt, P02461)
Open in Phaseline: the race on COL3A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Endo USA Inc., a Keenova Therapeutics Company | Collagenase Clostridium Histolyticum (KN3835) Collagen hydrolytic enzyme | COL1A2, COL1A1, COL2A1, COL3A1, COL4A1 | Phase 3 | Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger … | Dec 2027 |
| Wang Jianliu | Recombinant Humanized Type III Collagen Lyophilized Fibers Intrauterine injection of recombinant humanized type III collagen to promote endometrial r | COL3A1 | Phase 2 | Atypical Endometrial Hyperplasia | Dec 2027 |
| Peking University People's Hospital | Recombinant Humanized Type III Collagen (rhCOL3) Type III Collagen - tissue protective factor and tumor microenvironment remodeler | COL3A1 | Phase 1 | Breast Cancer | Dec 2028 |
Peyronie Disease (2) Breast Cancer (1) Flexible Hammertoe (1) Peyronie's Disease (1) Dupuytren Disease of Finger (1) Dupuytren Contracture (1) Atypical Endometrial Hyperplasia (1)
protein or peptide (2), small molecule (1)
Peking University People's Hospital (1) Endo USA Inc., a Keenova Therapeutics Company (1) Wang Jianliu (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.